New perspectives in the treatment of atopic dermatitis;Nuevas perspectivas en el tratamiento de la dermatitis atópica

Allergologia et Immunopathologia

Volumn 30, Issue 3, 2002, Pages 134-140

  Ortiz De Frutos, F Javier ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Anti leukotrienes; Atopic dermatitis; Atopic eczema; Montelukast; Pimecrolimus; Tacrolimus; Treatment; Zafirlukast; Zileuton

Indexed keywords

ANTIINFLAMMATORY AGENT; CALMODULIN; CORTICOSTEROID; CYTOKINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; MONTELUKAST; PIMECROLIMUS; TACROLIMUS; ZAFIRLUKAST; ZILEUTON; ANTIALLERGIC AGENT; IMMUNOSUPPRESSIVE AGENT;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BURN; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE ACTIVATION; DERMATITIS, ATOPIC; IMMUNOLOGY; TRENDS;

ALLERGY AND IMMUNOLOGY; ANTI-ALLERGIC AGENTS; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 0041813067     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-0546(02)79106-4     Document Type: Conference Paper

References (38)

1. Tacrolimus. The drug for the turn of the millennyum?
2. The mechanism of action of cyclosporin A and FK506
3. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis
4. A short-term trial of tacrolimus ointment for atopic dermatitis
5. Successful treatment of resistant facial lesions of atopic dermatitis with FK 506 ointment
6. Tacrolimus oinment gor atopic dermatitis
7. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment If atopic dermatitis
8. Tacrolimus (FK 506) oinment for atopic dermatitis: A phase I study in adults and children
9. Long-term study of FK506 (tacrolimus) ointment in patients with atopic dermatitis: Analysis at the time of 1-year observation
10. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients
11. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: Part I, efficacy
12. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children
13. Topical FK 506: Clinical potential or laboratory curiosity?
14. A local lymph node assay to analyse immunosuppressive effects of topically applied drugs
15. Inhibition of contact allergy reactions by topical FK 506
16. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
17. First experience of topical SDZ ASM 981 in children with atopic dermatitis
18. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment If atopic dermatitis
19. Nonclinical and early development of tacrolimus ointment for the treatment of atopic dermatitis
20. A late phase II study to determine the concetnration of FK506 (tacrolimus) ointment in atopic dermatitis (Part 1): Revised version
21. Phase III comparative study of FK506 ointment vs betamethasone valerate ointment in atopic dermatitis (trunk/extremities)
22. Phase III comparative study of FK506 ointment vs alclometasone dipropionate ointment in atopic dermatitis (face and neck)
23. Tacrolimus ointment for the treatment of atopic dermatitis in adults patients: Part II, Safety
24. Increased expression of epidermal IL-8 receptor in psoriasis: Down-regulation by FK 506 in vitro
25. Differential inhibition of cutaneous T-cell-mediated reactions and epidermal cell proliferation by cyclosporin, FK 506, and rapamycin
26. Tacrolimus oinment does not affect colagen synthesis: Results of a single-center randomized trial
27. Tacrolimus ointment does not affect collagen synthesis: Results of a single-center randomized trial
28. New approches to topical therapy
29. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology
30. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis
31. SDZ ASM 981: An emerging safe and effective treatment for atopic dermatitis
32. First experience of topical SDZ ASM 981 in children with atopic dermatitis
33. The leukotriene antagonist Zafirlukast as a therapeutic agent for atopic dermatitis
34. Treatment of atopic dermatitis with zafirlukast
35. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis
36. A randomized trial of leukotriene receptor antagonist montelukast in moderate-to-severe atopic dermatitis of adults
37. Montelukast in the treatment of children with moderate-to-severe atopic dermatitis: A pilot study
38. A pilot study examining the role of zileuton in atopic dermatitis